Patient and Public Involvement (PPI) in outcome selection in breast cancer and nephrology trials

Trials

Letter

Shaun Treweek¹  Lynn Laidlaw²  Ciara Buckley³  Frances Shiely³ 

[1] Health Services Research Unit, University of Aberdeen, Aberdeen, UK;Patient and Public Contributor, Health Service Research Unit, Aberdeen, UK;Trials Research and Methodologies Unit, HRB Clinical Research Facility, University College Cork, Cork, Ireland;School of Public Health, University College Cork, Cork, Ireland;HRB Trials Methodology Research Network (TMRN), University College Cork, Cork, Ireland;

关键词: Trial methodology;    Outcomes;    Clinical trials;    Patient and public involvement/PPI;   

DOI  :  10.1186/s13063-022-06980-9

 received in 2022-09-09, accepted in 2022-11-30,  发布年份 2022

来源: Springer

【 摘 要 】

We recently reported that according to patients and healthcare professionals in breast cancer and nephrology trials, teams conducting the trials got their choice of primary outcome wrong (72% of the time) more often than they got it right (28% of the time). A Patient and Public Involvement (PPI) representative, co-author of this letter, asked (on Twitter) whether PPI contributors had been involved in the design of the original trials and by extension the outcome selection. The purpose of this study was to answer this question.

【 授权许可】

CC BY   
© The Author(s) 2023